11-05 :: May/June 2011


nanotimes


Companies Facts


using 30nm class four gigabit (Gb) DDR3 DRAM chips.Samsung’s 30nm-class 4Gb DDR3 chip offers an approximate 50% increase in productivity over a 40nm-class 4Gb DDR3, and as a result is expected to achieve rapid market penetration. Samsung started producing monolithic 4Gb DDR3 DRAM devices based on 30nm-class technology in February, which is only one year after it started producing 40nm-class 4Gb DDR3 DRAM devices. Just two months later, it began to provide 16GB modules to a number of server system manufacturers. http://www.samsung.com/GreenMemory


Solazyme is offering 10,375,000 shares, and selling stockholders are offering 600,000 shares. Head- quartered in South San Francisco, USA, Solazyme, Inc. is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. http://www.solazyme.com


S


tarpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) announced successful results


of a major phase 2 clinical study that demonstrated efficacy of VivaGel® vaginosis (BV).


for the treatment of bacterial Key Points: • VivaGel® • VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV; expected to avoid many shortcomings of existing therapies;


• Trial results support new patent filing which extends VivaGel®


S


olazyme‘s shares begun trading on the NASDAQ Global Select Market on May 27, 2011 under the ticker symbol “SZYM”.


In May 2011, the Compa- ny announced the pricing of its initial public offering of 10,975,000 shares of common stock at a price to the public of $18.00 per share. Of the shares of com- mon stock in the offering,


• BV prevention trial of VivaGel® 2011;


protection to at least 2032;


• Planning underway for Phase 3 trials for VivaGel® for BV treatment;


to commence Q3


• Addressable global market for BV treatment and prevention potentially exceeds $1B.


In May, Starpharma Holdings has signed a licence agreement with Okamoto Industries Inc (TSE: JP3192800005) in relation to the VivaGel®


43


-coated


condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market. http://www.starpharma.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95